Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2007-09-30
2011-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypothesis: BOLD-MRI is a feasible tool to assess endothelial function in the human forearm during reactive hyperemia. There is significant correlation to established flow-mediated dilation (FMD).
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
One day: 2 CMR studies without contrast agent to assess endothelial function during reactive hyperemia. Each will last 15 minutes. A 15 minutes upper arm occlusion with a pressure cuff in between the 2 measurements will be applied.
Another day: 2 FMD studies with ultrasound to assess endothelial function during reactive hyperemia. Each will take 15 minutes. Simultaneously a PAT hyperemic index will be measured. A 15 minutes upper arm occlusion with a pressure cuff in between the 2 measurements will be applied.
Blood work (fasting glucose, creatinine, lipids, hsCRP), performed by Calgary Labs Services (CLS).
The effect of the reperfusion ischemia will be tested by individually comparing the BOLD signal change (BC) at baseline with BC after reperfusion ischemia. Since these are paired, related data a Wilcoxon rank sum test will be performed and a p value \< 0.05 will be regarded as significant. The same will be done for the FMD and PAT index before and after reperfusion ischemia.
FMD as the most accepted technique and will be considered as gold standard and a linear regression analysis of FMD with MBC and TBC will be performed. r2-value will be calculated and a value of \> 0.25 will be considered as reasonable of \> 0.5 as good correlation. If the correlation does not appear linear a Spearman's correlation test will be done.
The correlations between PAT index and FMD and PAT index and TBC will also be assessed with linear regression analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI before 15 min. ischemia reperfusion of forearm
No interventions assigned to this group
B
Endothelial Function of forearm assessed by FMD, PAT, BOLD-MRI after 15 min. ischemia reperfusion
ischemia reperfusion
reperfusion after a 15 min. lasting cuff induced arm ischemia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ischemia reperfusion
reperfusion after a 15 min. lasting cuff induced arm ischemia
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* male gender
* age \> 18 years
* fasting for 4 hours prior to the study and especially no coffee
Exclusion Criteria
* female gender
* known cardiovascular disease including: CHD, congestive heart failure, peripheral vascular disease
* known cardiovascular risk factors : smoking, diabetes mellitus, hypertension, hyperlipidemia
* Current vasoactive medication : Beta-blockers, Ca-Antagonists, ACE-Inhibitors, ARB, Phosphodiesterase inhibitors
* concomitant serious medical condition
* unreliability as a volunteer or inability or unwillingness to complete the study and the second day of examination
18 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Calgary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Oliver Strohm
Adunct Research Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthias Friedrich, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stephenson CMR Centre at Foothills Medical Centre, University of Calgary
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol #21003
Identifier Type: -
Identifier Source: secondary_id
E-21003
Identifier Type: -
Identifier Source: org_study_id